News
Cambridge, UK, and Cambridge, MA, 08 September 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and XtalPi Inc., a leading algorithm-driven artificial intelligence (AI)-based pharmaceutical technology company, today announced they have entered into a drug discovery collaboration agreement. Financial details are not disclosed.
CAMBRIDGE, UK 09 September 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced a collaboration with leading, global high-performance analog technology company, Analog Devices, Inc. The companies will work together on the advancement and commercial scale-up of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips and accelerate the development of Evonetix’s first product, a DNA desktop writer.
- TTP will provide entrepreneurs with mentoring and tech consultancy, to accelerate product development and commercialisation
- Agreement underlines TTP’s commitment to sharing knowledge and experience with innovative start-ups
- TTP to deliver virtual seminar on 17 September as part of Start Codon and Cancer Research UK’s Entrepreneurial Training Scheme
Executive search consultancy, Horton International UK, has announced the appointment of Mark Johnson as Senior Partner of its Oxford-based Global Healthcare arm.
AMSBIO announce new additions and certifications for their market-leading range of clinical grade, chemically defined cryopreservation excipient solutions - STEM-CELLBANKER® and HSC-BANKER®.
Cambridge, UK, 01 September 2020: Mursla, a liquid biopsy company, has raised £410K from the UK Government’s Future Fund and existing investors. In addition, the organisation has secured a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme.
The funding will enable Mursla to finalise its work on its novel exosome-based liquid biopsy platform, ExoPhenoTM, with the aim of demonstrating how the platform can detect cancer signatures in plasma from solid tumours via exosomes.
Free COVID-19 risk assessment services are being offered by Bishop Simon. Bishop Simon is a Health, Safety and Biosafety Consultancy. Our Chartered Health and Safety Consultants have served, many scientific research organisations including the Medical Research Council and PSI (CRO). If you would like to tap into or expertise to carry out your COVID-19 risk assessment, review your current COVID-19 risk assessment or inspect your COVID measures then please contact us.